Patents by Inventor Marina Kopp

Marina Kopp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7361662
    Abstract: A compound of formula (I): wherein: R1, R2, R3, R4 are defined in the description, its enantiomers, diastereoisomers, tautomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as kinase modulators.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: April 22, 2008
    Assignee: Les Laboratoires Servier
    Inventors: Sylvain Rault, Jean-Charles Lancelot, Marina Kopp, Daniel-Henri Caignard, Bruno Pfeiffer, Pierre Renard
  • Patent number: 7098220
    Abstract: Compounds of formula (I): wherein: R1 represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl, R2 represents hydrogen, alkyl, an optionally substituted aryl, optionally substituted heteroaryl, or R20—C(X)— wherein: R20 represents alkyl, alkoxy, amino, alkylamino, dialkylamino, optionally substituted aryl or optionally substituted heteroaryl, X represents oxygen, sulphur, or NR21 wherein R21 represents hydrogen or alkyl, R3 represents hydrogen atom or alkyl, n represents integer from 1 to 6 inclusive, the representation its enantiomers, diastereoisomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as AMPK activators.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: August 29, 2006
    Assignee: Les Laboratoires Servier
    Inventors: Sylvain Rault, Jean-Charles Lancelot, Marina Kopp, Daniel-Henri Caignard, Bruno Pfeiffer, Jean-Guy Bizot-Espiard, Pierre Renard
  • Publication number: 20060069117
    Abstract: Compounds of formula (I): wherein: R1 represents hydrogen, halogen, alkyl, polyhaloalkyl, cyano, nitro, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl, R2 represents hydrogen, alkyl, an optionally substituted aryl, optionally substituted heteroaryl, or R20—C(X)— wherein: R20 represents alkyl, alkoxy, amino, alkylamino, dialkylamino, optionally substituted aryl or optionally substituted heteroaryl, X represents oxygen, sulphur, or NR21 wherein R21 represents hydrogen or alkyl, R3 represents hydrogen atom or alkyl, n represents integer from 1 to 6 inclusive, the representation its enantiomers, diastereoisomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as AMPK activators.
    Type: Application
    Filed: November 4, 2003
    Publication date: March 30, 2006
    Inventors: Sylvain Rault, Jean-Charles Lancelot, Marina Kopp, Daniel-Henri Caignard, Bruno Pfeiffer, Jean-Guy Bizot-Espiard, Pierre Renard
  • Publication number: 20050288311
    Abstract: A compound of formula (I): wherein: R1, R2, R3, R4 are defined in the description, its enantiomers, diastereoisomers, tautomers and also addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful as kinase modulators.
    Type: Application
    Filed: November 4, 2003
    Publication date: December 29, 2005
    Inventors: Sylvain Rault, Jean-Charles Lancelot, Marina Kopp, Daniel-Henri Caignard, Bruno Pfeiffer, Pierre Renard
  • Publication number: 20050143440
    Abstract: Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.
    Type: Application
    Filed: March 1, 2005
    Publication date: June 30, 2005
    Applicant: LES LABORATORIES SERVIER
    Inventors: Sylvain Rault, Marina Kopp, Jean-Charles Lancelot, Stephane Lemaitre, Daniel-Henri Caignard, Jean-Guy Bizot-Espiard, Pierre Renard
  • Patent number: 6875788
    Abstract: Compounds of formula (I): wherein: R1 represents an optionally substituted heteroaryl group, R2 represents an optionally substituted cycloalkyl group, R3 represents a hydrogen atom or an alkyl group, and R4 and R5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: April 5, 2005
    Assignee: Les Laboratoires Servier
    Inventors: Sylvain Rault, Marina Kopp, Jean-Charles Lancelot, Stéphane Lemaitre, Daniel-Henri Caignard, Jean-Guy Bizot-Espiard, Pierre Renard
  • Publication number: 20040087638
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: October 20, 2003
    Publication date: May 6, 2004
    Inventors: Sylvain Rault, Marina Kopp, Jean-Charles Lancelot, Stephane Lemaitre, Daniel-Henri Caignard, Jean-Guy Bizot-Espiard, Pierre Renard